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ABSTRACT:
The intracellular location and regulation of proteins within each cell is critically 
important and is typically deregulated in disease especially cancer. The clinical 
hypothesis for inhibiting the nucleo-cytoplasmic transport is based on the dependence 
of certain key proteins within malignant cells. This includes a host of well-characterized 
tumor suppressor and oncoproteins that require specific localization for their function. 
This aberrant localization of tumour suppressors and oncoproteins results in their 
their respective inactivation or over-activation. This incorrect localization occurs 
actively via the nuclear pore complex that spans the nuclear envelope and is mediated 
by transport receptors. Accordingly, given the significant need for novel, specific 
disease treatments, the nuclear envelope and the nuclear transport machinery have 
emerged as a rational therapeutic target in oncology to restore physiological nucleus/
cytoplasmic homeostasis. Recent evidence suggests that this approach might be of 
substantial therapeutic use. This review summarizes the mechanisms of nucleo-
cytoplasmic transport, its role in cancer biology and the therapeutic potential of 
targeting this critical cellular process
INTRODUCTION  
The physical separation of the genome from the 
cytoplasm by the nuclear envelope (NE) is a hallmark 
of the eukaryotic cell creating a requirement to transport 
macromolecules across the nuclear membrane to meditate 
their normal function(s). This transport process is highly 
coordinated and is an important regulator of cell signalling 
(to growth signals or various stresses). The separation of 
proteins from their site(s) of function is a recurrent motif 
ensuring the fidelity of signal transduction and preventing 
aberrant activation. Many transcription factors reside in the 
cytoplasm in an inactive form until activation is triggered 
that results in their translocation into the nucleus. Upon 
nuclear entry they direct specific transcriptional programs 
determining cell fate [1]. Cancer cells utilize the aberrant 
localization of tumor suppressor proteins as a means for 
their inactivation and to effectively evade anti-neoplastic 
therapies [2]. The aberrant localization of oncoproteins can 
also lead to their inadequate activation [3]. Our growing 
understanding of the mechanisms that control the nucleo-
cytoplasmic transport has directed the development new 
exciting therapeutic avenues to target cancers that display 
aberrant protein subcellular localization. 
The nucleoplasmatic transport 
Protein transport is a critical, highly regulated 
process ensuring that the nuclear entry of proteins through 
the nuclear pore complex (NPC) only occurs when 
their functions are required and to export them into the 
cytoplasm when they are not needed. For nuclear entry, 
proteins must negotiate the NPC that is comprised of 
over 30 different protein components called nucleoporins 
(Nups) [4]. While proteins less than 40 kDa in size are 
able to freely traverse the NPC, larger proteins and 
molecules require active transport that is directed by 
nuclear localization or nuclear export sequences (NLS or 
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NES) [5]. Import is controlled by importins (either α or β 
sub-types). After being bound by importin, the resulting 
cargo protein-importin complex is brought inside the 
nucleus via Nups located within the NPC itself. Once 
this protein-protein complex has entered the nucleus, the 
cargo/transport protein complex is bound by Ran-GTP 
dissociating the transport components. This releases the 
cargo protein allowing it to direct its function(s) within the 
nucleus and enables the recycling of the transport proteins 
for subsequent rounds of nuclear transport. The export of 
proteins from the nucleus is controlled by the recognition 
of a leucine rich sequence (NES) within the cargo protein 
by CRM1/exportin1. This binds to Ran-GTP and traverses 
the NPC into the cytoplasm. The conversion of Ran-GTP 
to Ran-GDP induces the dissociation of the complex 
allowing the recycling of the export molecules. 
Nucleoporins and cancer
Several Nups have been linked to tumor formation 
and progression [6]. The nucleoporin Rae1 (Gle2) plays an 
important role in RNA export [7] and is linked to breast 
cancer pathology [8]. The over expression or the depletion 
of Rael1 directs the formation of multi-polar spindles and 
promotes aneuploidy [9]. Nup98 is also a well indentified 
proto-oncogene in leukemia [10] and is also part of a 
recurrent chromosomal translocation event observed in 
acute myeloid leukemia patients [11]. TPR (translocated 
promoter region and part of the NPC), was named after 
its initial isolation from a carcinogen treated asteogenic 
sarcoma cell line as part of a chromosomal translocation 
event that fused the N-terminal sequence of TPR to the 
kinase domain of the proto-oncogene Met [12], an early 
step in the formation of gastric carcinomas [6]. Nup88 
is over expressed in ovarian cancer [13], lymphomas, 
mesotheliomas, a broad spectrum of sarcomas and in 
some epithelial cancers [14] In breast, colorectal and 
hepatocellular carcinoma Nup88 over expression is 
associated with tumor aggressiveness [15].
Nuclear Transport Receptors  (NTRs) and cancer
The over expression of karyopherin-β family 
members is observed in colon, breast and lung cancer 
[16;17] while the deregulation of karyopherin-α2 
expression in breast cancer and melanoma correlates 
with poor prognosis and reduced overall survival [16]. 
Elevated CRM1 expression correlates with poor clinical 
Table 1: Differential subcellular localization of proteins in human cancer
Protein Function Cancer Normal Localization Mislocalization Reference
FOXO Transcription factor Various types of cancer Nucleus Cytoplasm [141]
β-Cantenin Wnt signaling Colorectal cancer Cytoplasm Nucleus [2] 
p53 Transcription factor Various types of cancer Nucleus Cytoplasm [142] 
Galectin-3 Beta-galactoside-BP Various types of cancer Nucleus Cytoplasm [141]
BARD1 BRAC1 interacting Protein Breast cancer Cytoplasm Nucleus [143]
BRAC1 DNA repair Breast cancer Cytoplasm Nucleus [64]
NF-kB Transcription factor Various types of cancer Cytoplasm Nucleus [144]
NPM1 Ribonucleoprotein AML Nucleolus Cytoplasm [145]
p21WAF1 Cell cycle inhibitor CML, ovarian, breast Nucleus Cytoplasm [146]
p27KIP Cell cycle inhibitor AML, breast Nucleus Cytoplasm [147]
RUNX3 Transcription factor Gastric cancer Nucleus Cytoplasm [148]
INI1 Tumor suppressor Rhabdoid tumors Nucleus Cytoplasm [149]
RB E2F BP Various types of cancer  Nucleus Cytoplasm [145]
HIF-1α Transcription factor Breast, prostate cancer Cytoplasm Nucleus [112]
NFAT Transcription factor Various types of cancer  Nuc/Cyt Nucleus [150]
PTEN Phosphatase Various types of cancer  Nuc/Cyt Cytoplasm [151]
Bcr-Abl Kinase CML Nuc/Cyt Cytoplasm [152]
Fbw7γ Ubiquitin ligase Various types of cancer  Nucleolus not nucleolar [153]
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outcome in ovarian [18], pancreatic [19], osteosarcoma 
[20], glioma [21] and cervical cancers [22]. Furthermore, 
the truncated form of karyopherin-α (that lacks the NLS 
binding domain) was observed in the breast cancer cell 
line ZR- 75-1 [23] resulting in the accumulation of p53 in 
the cytoplasm. In addition to karyopherin-α truncations, 
CAS (a factor that regulates karyopherin-α movement) 
is over expressed in breast cancers [24] liver neoplasms 
[24;25] and colon cancer cell lines [26]. Consequently any 
change in the expression of CAS can significantly affect 
the nuclear transport and subcellular distribution of tumor 
suppressors and oncoproteins.Nucleoplamic transport of 
tumor suppressors and oncogenic proteins
Considering the importance of the subcellular 
localization of proteins it is not surprising that the 
disruption of nuclear-cytoplasmic transport is oncogenic 
and a potent mechanism for cancer cells to evade and 
develop resistance to chemotherapeutic treatments. This 
is striking as drug resistance continues to be one of the 
most significant obstacles for the effective treatment 
of cancer and offers the cancer cell the ability to gain 
resistance to a broad range of chemotherapeutic drugs 
whose mechanisms of action could be highly divergent. 
A number of the major oncogenes and tumour suppressors 
with aberrant subcellular localization in cancer are shown 
in Table 1. Proteins that exert essential functions within 
the nucleus to prevent cancer initiation, progression 
or to direct the cellular response to chemotherapeutic 
assault include p53, FOXO(s), p27, BCRA1, APC, 
nucleophosmin and retinoblastoma (Rb). In contrast, the 
activation and cellular mis-localization of pro-survival 
and proliferation proteins such as β-catenin, NF-κB, 
survivin or cyclin D1 have been reported in various types 
of cancers [2;27]. Given these observations, the proteins 
involved in the subcellular localization of these factors 
are highly attractive therapeutic targets as they are both 
essential while the restoration of their aberrant function(s) 
would not be detrimental to non-cancerous cells.
p53
The tumor suppressor and transcription factor p53 is 
one of the most commonly mutated proteins in all human 
cancers indicating its vital role in genome protection [28]. 
The majority of these mutations target the DNA binding 
ability of p53 [29] although this is not always the case. In 
several types of cancer (including breast, colon, ovarian, 
retinoblastoma and neuroblastoma) the inactivation of 
wild-type p53 is by abnormal cytoplasmic localization 
[30;31]. In these situations, the functionality of the p53 
protein (including its ability to bind DNA) remains intact 
and p53 activity is, in principle restorable by relocating 
the protein into the nucleus. p53 contains both NLS and 
NES signals that mediate nuclear import and nuclear 
export via importin-α/ß and CRM1. The NLS is adjacent 
to, and the NES is contained within, the oligomerization 
domain of p53 raising the possibility that oligomerization 
of p53 may regulate p53 nucleo-cytoplasmic transport 
by affecting the accessibility of the NLS and/or the NES 
to their respective receptors. Following cellular stress 
p53 is post-translationally modified and translocates 
into the nucleus where it induces the transcription of 
its target genes driving cell cycle arrest of apoptosis 
[32]. In addition to directing p53 to the proteosome for 
degradation, p53 ubiquitination (by MDM2) also functions 
as a signal for degradation-independent roles that includes 
nuclear export. While polyubiquitinated p53 is targeted 
for proteasomal degradation, mono-ubiquitinated p53 is 
specifically targeted for nuclear export [33;34] and directly 
contributes to the cellular choice between cell cycle arrest, 
senescence or apoptosis. 
The cytoplasmic sequestration of p53 in 
neuroblastoma typically results from a MDM2 
amplification event and subsequent mono-ubiquitination 
[35]. The deregulated subcellular localization of p53 
presents an extremely interesting drug target. For 
example, the inactivation of PARC by RNAi results in the 
restoration of nuclear p53 and restores the p53-mediated 
response to stress [36;37]. Nutlins are cis-imidazoline 
analogs that target the interaction between MDM2 and 
p53 preventing the degradation of p53 and allowing the 
p53 to accumulate. This accumulation enables p53 to 
induce senescence and apoptosis and is being tested to 
treat tumors that contain normal or wild type p53 [38]. In 
addition, all-trans-retinoic acid (RA) and retinoids inhibit 
the nuclear accumulation of p53 without substantially 
affecting its steady-state level. This suggests that nuclear 
import of p53 is an independent and active process that can 
be selectively regulated and targeted by RA to modulate 
chemoresistance [39]. However to ensure that the nuclear 
retention of p53 would be an effective treatment, patient 
screening is required to determine if their tumor contained 
wild-type p53. Despite this limitation, p53 remains a prime 
target for ongoing cancer drug development particularly in 
a personalized medicine context [40;41].
FOXO proteins
Class O forkhead box (FOXO) proteins are a family 
of transcription factors (FOXO1, FOXO3a, FOXO4, and 
FOXO6) that control a number of essential cellular roles 
including cell cycle progression, metabolism, apoptosis, 
and stress resistance [42]. FOXO activity is regulated 
by subcellular translocation, DNA binding and protein 
degradation [43]. FOXO inhibition occurs through PI3K/
Akt signalling whereas FOXO activation (via reactive 
oxygen signalling [ROS]) has been shown to converge 
in regard to the regulation of FOXO translocation. All 
FOXO proteins contain a non-classical bipartide NLS 
consisting of two clusters of arginine and lysine residues 
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positioned on both sides of an Akt/14-3-3 binding motif in 
the C-terminus of the forkhead domain. Phosphorylation 
of the Akt introduces a negative charge in the basic 
stretch of residues that is required for NLS function, 
thereby inhibiting nuclear translocation of FOXO. In 
contrast the identity of the nuclear import receptors for 
FOXO proteins remains largely unknown. A recent 
publication suggests that distinct nuclear import pathways 
control ROS-dependent and insulin signalling-dependent 
nuclear localization of FOXO [44] and that ROS induce 
the formation of a disulfide bond between FOXO4 and 
transportin-1. This interaction is required for efficient 
nuclear localization of FOXO4 upon ROS signalling but 
not upon loss of insulin signalling [44]. FOXO proteins 
also contain a NES which mediates the CRM1-dependent 
nuclear export of non-DNA bound FOXO. The exposure 
of the FOXO-NES motif is facilitated by the binding of the 
chaperone protein 14-3-3 to FOXO proteins in the nucleus 
enabling their active export. 14-3-3 binding is regulated 
in response to growth signals by Akt and related SGK 
mediated phosphorylation of FOXO [45]. The activity 
of FOXO transcription factors is also controlled by other 
types of post-translational modifications that include 
non-Akt/SGK-mediated phosphorylation, acetylation, 
methylation, glycosylation and monoubiquitination. 
The restoration of nuclear FOXO localization has been 
highlighted as a promising strategy to treat certain types 
of cancer and accordingly, the forced expression of nuclear 
FOXO has been shown to induce apoptosis in a wide range 
of cancer cells including prostate, and breast cancers as 
well as in malignant melanoma [46-51]. 
While it is highly tempting to therapeutically inhibit 
PI3K/Akt (that is constitutively active in many cancers) 
driving the accumulation of nuclear FOXO [52], a recent, 
important study revealed that in the presence of high 
nuclear β-catenin, that the activation of FOXO3a by PI3K 
or Akt inhibitors induced metastasis rather than mediating 
a pro-apoptotic anti-tumor response as would have been 
predicted [53]. This raises the hypothesis that the β-catenin 
status within patient carcinomas must be evaluated prior 
to deciding on this course of treatment. This evaluation 
would be essential for both the provision of a safer and 
more effective personalized treatment of colon cancer. 
Importantly, pharmaceutically strategies to induce nuclear 
exclusion of β-catenin might significantly improve clinical 
outcomes in these patients. Regardless, while there are 
some limitations, the FOXO family of proteins remains a 
viable and highly investigated anti-cancer target.
p27 
The cyclin-dependent kinase (CDK) inhibitor 
p27 displays aberrant subcellular localization in many 
cancers. In normal cells, p27 is localized in the nucleus 
where it binds to and inhibits CDK2, an activator of 
E2F1 transcription factors, promoting DNA replication 
[54;55]. To export p27 from the nucleus (via CRM1), 
p27 phosphorylated at serine 10 is required. Following 
this modification, p27 is exported into the cytoplasm 
and degraded by the cullin-RING ubiquitin ligase 
CRL1SKP2. The constitutive activation of Akt promotes 
this post-translational modification and directs the mis-
localisation of p27 into the cytoplasm [56]. High levels 
of (cytoplasmic) phosphorylated serine 10-p27 have also 
been observed in glioma patients and correlated with 
both grade and clinical prognosis. In other carcinomas 
such as oesophagus, thyroid, colon and p27-positive 
breast carcinomas, p27 localization is also predominantly 
cytoplasmic thus allowing CDK2 to activate E2F1. 
This activation promotes cell-cycle progression driving 
tumorigenesis. To compound this further, Akt-mediated 
phosphorylation of the NLS within p27 also inhibits 
nuclear import further promoting the cytoplasmic 
sequestration of p27 [57], in a manner similar to the 
FOXO transcription factors discussed above. 
p27 is an interesting therapeutic target as a number 
of compounds are being screened and evaluated [58] with 
particular attention focused on compounds that directly 
disrupt the binding of phosphorylated p27 to the CRL1 
substrate receptor (SKPins) [59]. This approach offers 
considerably higher target specificity compared to broad 
proteasome inhibitors such as Bortezomib or Carfilzomib 
that are currently administered in the clinic that are 
associated with significant toxicity and patient side effects. 
Clearly before administering these compounds, aberrant 
p27 localization would need to be observed and thus 
underpins a personalized treatment platform for colon, 
glioma and breast cancer.
BRCA1
The breast cancer susceptibility gene 1 (BRCA1) 
product has multiple roles within the cell, interacting with 
tumor suppressors, DNA repair proteins and cell cycle 
regulators [60]. Due to the significant size of the protein 
(220 kDa) BRCA1 can only enter the nucleus via active 
transport. BRCA1 contains two NLS within a single exon 
[61] and is transported into the nucleus by the importin-
α/ß pathway [62]. BRCA1 can also form a protein-protein 
complex with the BRCA1-associated RING domain 
protein 1 (BARD1) and following this interaction can 
also accumulate within the nucleus without requiring the 
BRCA1 NLS [63]. While nuclear accumulation is clearly 
evident BRCA1 also undergoes receptor-mediated nuclear 
export [64]. BRCA1 has a Rev-like NES that is classically 
bound by CRM1 and more interestingly BARD1 has been 
shown to mask the BRCA1 NES, indicating that BARD1 
can regulate both the nuclear import and export of BRCA1 
[65]. Due to the extremely complex regulation of BRCA1 
subcellular localization, it is not surprising that a plethora 
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of mutations were characterized from breast cancer 
patients resulting in either the loss or gain of BRCA1 
function. 
PARP (poly (ADP-ribose) polymerase) inhibitors 
have been shown to be effective in treating BRCA1-
mutated tumors. The therapeutic exclusion of BRCA1 
from the nucleus could significantly sensitize cancers to 
PARP inhibitors, increasing the effectiveness of these 
compounds and/or reducing the effective concentration 
required, minimizing patient toxicity. In the context of a 
personalized medicine approach this could enable PARP 
inhibitor regimes to be used to treat tumors that display 
non-mutated, nuclear BRCA1 [64;66;67]. Given the 
increasing emergence of drug resistant breast cancers and 
the molecular profiling already conducted from breast 
cancer biopsies, the incorporation of BRCA1 status/
localization could offer significant hope to patients who 
fail to respond to conventional therapeutics.
β-Catenin
ß-catenin has been shown to be a key component of 
the Wnt signalling pathway. Most cases of colon cancer 
are initiated by the nuclear accumulation of the β-catenin 
protein following mutation or due to the inactivation of 
the adenomatous polyposis coli (APC) tumor suppressor 
that regulates β-catenin stability. In the absence of 
Wnt signalling, β-catenin is rapidly phosphorylated by 
APC and glycogen synthase kinase 3 beta (GSK-3β). 
Phsophorylated β-catenin is quickly degraded in an 
ubiquitin- preoteosome-dependent manner allowing APC 
to maintain a low level of β-catenin within the cell. Wnt 
binding to Frizzled (Fz) and Lrp5/6 inhibits the APC 
complex which allows the β-catenin protein to accumulate 
and enter the nucleus, driving β-catenin-dependent gene 
expression [68]. Within the literature there remains 
no consensus regarding the mechanism of β-catenin 
subcellular localization although it is known that nuclear 
import is independent of the NLS/importin machinery. 
Protein structure and sequence studies demonstrated 
that β-catenin is a close relative of importins and can 
directly interact with the NPC [69]. β-catenin can also 
be transported back into the cytoplasm bound to Axin 
(a negative regulator of the Wnt signalling pathway), 
independent of its degradation role [70] or when in a 
protein complex with APC, migrating from the cytoplasm 
and the nucleus [71]. 
Given the widespread anomalous Wnt mediated 
signalling in cancer, targeting the nuclear localization of 
β-catenin represents a very attractive therapeutic strategy. 
As β-catenin does not rely on the classic nuclear import 
and export pathways, it presents a unique opportunity 
to specifically interfere with its nucleo-cytoplasmic 
transport without significantly affecting non-transformed 
cells. Therapeutic molecules that mediate the specific 
nuclear exclusion of β-catenin together with companion 
diagnostic tests to identify patients who may benefit from 
this treatment could lead to major breakthroughs in colon 
cancer treatment and disease management.
APC
As mentioned above, the tumor suppressor APC 
regulates many cellular functions and promotes the 
degradation of β-catenin. In non transformed cell, APC is 
distributed evenly between the nucleus and cytoplasm with 
no significant accumulation in either compartment. APC 
itself is mutated in approximately 80% of all colon cancer 
patients [72] with the most common mutation resulting in 
a stable, truncated form of the protein that accumulates in 
the nucleus. The APC protein contains multiple NLS and 
NES signals and has been shown to shuttle between the 
nucleus and cytoplasm.  It has been reported that an APC 
protein that lacks a functional NLS or NES signals fails to 
effectively down regulate nuclear β-catenin levels and this 
is also observed in cells that express wild-type APC that 
have nuclear export blocked [73]. 
Like β-catenin, APC is an attractive therapeutic 
target [74], particularly in regard to retaining or trapping 
APC within the cytoplasm. A complementary approach 
with compounds that mediate β-catenin nuclear exclusion 
could significantly improve the clinical outcome of colon 
cancer patients as targeting two deregulated molecular 
events could result in a highly cancer specific treatment 
regime with a reduced possibility of drug resistance. 
NF-κB
The transcriptional activator, nuclear factor-κB 
(NF-κB), has been widely described in tumorigenesis and 
chemotherapy resistance. In non-cancerous cells, NF-κB 
forms a complex with the inhibitor IκB, which masks the 
NLS on NF-κB and prevents translocation of NF-κB to the 
nucleus. In non-transformed cells, IκB is phosphorylated 
and degraded by the proteasome revealing the NF-κB 
NLS enabling nuclear import [75]. In order to direct 
NF-κB into the cytoplasm, p300-mediated acetylation of 
NF-κB occurs, preventing assembly with IκB facilitating 
CRM1-dependent nuclear export via the NES presentation 
by NF-κB [76]. NF-κB is predominantly localized inside 
the nucleus in many cancers (for example Hodgkin’s 
lymphoma, childhood acute lymphoblastic leukaemia, 
breast, colon and pancreatic cancers). This nuclear mis-
localization can be attributed to defective IκB activity, 
hyperactivation of upstream kinases that result in IκB 
phosphorylation and degradation, or improper aceylation 
by p300 [76]. NF-κB contains classical NLS motifs and 
is imported into the nucleus via the importin α/β pathway. 
Since the nuclear localization of NF-κB subunits is a 
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hallmark of a constitutively activated pathway and that 
this has been demonstrated to be essential for several 
types of human tumors, the inhibition of NF-κB nuclear 
import could prove highly beneficial for therapy against 
these cancers [77].
Nucleophosmin
Nucleophosmin is a multifunctional protein that 
regulates ribosome biogenesis, RNA transcription, histone 
assembly and DNA repair [78]. This diverse range of roles 
reflects its function as either an oncoprotein or tumor 
suppressor. Nucleophosmin is localized in the cytoplasm 
following apoptotic stimuli [79;80] and mediates 
this cellular response by regulating Bax activation. 
Nucleophosmin redistribution within the cell occurs prior 
to Bax translocation to the mitochondria. Nucleophosmin 
contains a NLS, a NES as well as a number of 
phosphorylation sites which control its cellular localization 
[81;82]. Despite the NES motifs, nucleophosmin remains 
localized within the nucleus indicating that under normal 
cellular conditions, its nuclear import is dominant over 
export, a process regulated by the Ran-CRM1 pathway 
[83]. Strikingly in acute myeloid leukaemia (with normal 
karyotype) there is aberrant nucleophosmin localization in 
the cytoplasm of cancer cells [84]. Molecular analysis of 
this cancer revealed that this was the result of an additional 
NES motif following a frame shift mutation, dramatically 
enhancing CRM1-dependent export [85].
Nucleophosmin is an interesting drug target, 
specifically retargeting it back into the nucleus to prevent 
its aberrant cytoplasmic accumulation. Once within the 
nucleus it could, in principle drive Bax translocation. 
This restoration would be highly effective if used in 
combination with compounds that activate Bax which 
have recently been identified and muted for potential 
clinical trial [86]. In a personalized medicine context, 
clinical samples would need to be evaluated for both 
aberrant nucleophosmin localization and the presence 
of Bax to mediate the cellular response following the 
retention of nucleophosmin within the nucleus. 
Survivin
Survivin is a member of the inhibitor of apoptosis 
protein (IAP) family that when it is localized within the 
nucleus, has a role in mitosis. In contrast, the cytoplasmic 
and mitochondrial localized survivin protein mediates 
an anti-apoptotic function [87-89]. The subcellular 
localization of survivin is CRM1/ NES–dependent. When 
the survivin-NES is mutated, trapping survivin within the 
nucleus, proper cell division does not occur and the anti-
apoptotic function of survivin is lost [90]. Many cancers 
(for example lung, colon, pancreas, prostate and breast), 
display an almost ubiquitous over expression of survivin 
compared to normal tissue correlating with clinical 
phenotype, resistance to therapy, and accelerated disease 
relapse [91;92]. Unlike within normal cells, survivin 
localization in cancer cells is at the inner mitochondrial 
membrane [88]. In non-transformed cells in response 
to an apoptotic stimulus, survivin is directed from the 
mitochondria to the cytosol where it inhibits apoptosis 
[88]. This function is dependent on the phosphorylation 
of survivin at residue Ser-20. This modification occurs 
in the cytosol but not in the mitochondria and it is this 
differential phosphorylation that regulates tumor cell 
apoptosis, modulating the interaction of survivin with the 
X-linked inhibitor of apoptosis protein (XIAP). 
Survivin is an interesting target [93] particularly 
when one considers restoring or targeting the subcellular 
localization of proteins. Trapping survivin within the 
nucleus would ablate the anti-apoptotic function of the 
protein, significantly sensitizing the cancer to various 
chemotherapeutic regimes; however this could support 
the mitotic functions of the protein, driving cell division. 
Conversely, preventing survivin from nuclear entry would 
remove the pro-division functions but would still retain the 
anti-apoptotic function(s). 
Retinoblastoma (Rb)
The retinoblastoma (Rb) family of proteins play a 
crucial role regulating the cell cycle controlling the G1-S 
phase transition functioning as a potent tumor suppressor. 
The inactivation of pRB not only allows inappropriate 
proliferation but also undermines mitotic fidelity that 
results in genome instability and ploidy changes. 
Retinoblastoma deficient cells have an altered regulation 
of the G1 checkpoint and altered levels of autophagy, 
apoptosis, angiogenesis, and metastatic potential [94]. 
During the cell cycle, pRb-E2F forms a protein-protein 
complex that prevents transcription of E2F-regulated 
genes required for cell cycle progression [95;96]. This 
interaction with E2F is dependent upon pRb remaining 
non-phosphorylated [97]. Once phosphorylated by 
cyclinD1/CDK, pRb is targeted to the cytoplasm allowing 
G1 progression. Given this crucial inhibitory role, it is 
not surprising that Rb inactivation is a hallmark of many 
cancers. 
The potency of Rb makes it an extremely attractive 
therapeutic target. Compounds that trap Rb within the 
nucleus of cancer cells could have a significant impact on 
a broad range of cancers, as these defects could represent 
an ‘Achilles heel’ that can be specifically enhanced in 
tumor cells. The nuclear retention of pRb could stabilize 
the cancer genome and inhibit tumor evolution, effects 
that that could complement and dramatically enhance the 
potency of traditional therapeutics. There is a however a 
possibility that trapping Rb within the nucleus could prove 
ineffective due to aberrant, constitutive cyclin D1 activity 
(discussed below) driving tumorgenesis.
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Cyclin D1
Cyclin D1 is a member of the cyclin family of 
proteins that function as regulators of Cyclin-dependent 
kinases (CDKs). Cyclin D1 forms a complex with 
CDK4 and CDK6. Upon entry into the nucleus, active 
cyclin D1/CDK4 and Cyclin D1/CDK6 complexes 
direct the phosphorylation of Rb. As described above, 
phosphorylated Rb protein is exported into the cytoplasm 
and releases the E2F transcription factor promoting 
the transcription of S-phase genes driving cell cycle 
progression. Due to the potency of cyclin D1, the level 
of this protein is very carefully regulated within the cell. 
Prior to the poly-ubiquitination of cyclin D1 there is the 
requirement for phosphorylation at Thr-286 by GSK-3β. 
GSK-3β is retained within the cytoplasm of a cell during 
G1 but enters the nucleus during S-phase allowing access 
to the cyclin D1/CDK complex. Upon phosphorylation 
at Thr-286 cyclin D1 can then be bound by CRM1 and 
shuttled into the cytoplasm and degraded [55].
Given the role of cyclin D1 to promote the cell 
cycle it was surprising that first, the amplification of the 
cyclin D1 locus is rarely observed in cancers with over 
expression of cyclin D1 and that second, the enforced over 
expression of cyclin D1 is not the transforming property of 
cyclin D1 [98]. Rather it is the nuclear retention of cyclin 
D1/CDK kinase that is the cancer predisposing mechanism 
[99]. A novel cyclin D1 isoform (cyclin D1b) was 
identified that lacks both the GSK-3β and CRM1 binding 
site and is constitutively nuclear [100]. This isoform is still 
capable of binding and activating CDK4 and is also able 
to dissociate pRb (ensuring its cytoplasmic localization 
and subsequent degradation) promoting the cell to 
divide. Another cyclin D1 mutation is a proline-serine/
threone substitution at residue 287 (preventing Thr-286 
phosphorylation by GSK-3β) producing a constitutively 
nuclear mutant [101]. In addition to these splice isoforms 
and direct mutations, the signalling pathways (Ras-PI3K-
Akt-GSK-3β) that regulate cyclinD1 localization are 
commonly deregulated in cancer. In light of these reports, 
it is thought that tumor suppression breaks down when 
the cell is no longer capable of shuttling cyclin D1 from 
the nucleus. As nuclear cyclin D1 is oncogenic, preventing 
the nuclear accumulation of this protein in patients with 
tumors that contain high levels of nuclear cyclin D1 could 
significantly improve clinical prognosis. 
Therapeutic Targeting of the Nucleo-cytoplasmic 
transport
Therapeutically targeting the nuclear transport of 
proteins is a very interesting option. Our understanding 
of this process has enabled specific regions of the 
transport process to be targeted, indicated in Figure 1. The 
restoration of nucleo-cytoplasmic homeostasis correcting 
the disrupted physiological localization of tumor 
suppressors (e.g. p53, FOXO, p27, APC) or directing the 
mislocalization of proteins to inactivate oncoproteins (e.g. 
β-catenin, NF-κB, or Survivin) is currently being tested. 
These approaches are limited as normal and cancer cells 
share similar core components of the export and import 
apparatus. However, recent progress in understanding 
the nucleo-cytoplasmic communication process and 
its role in tumor formation and progression provides a 
previously unrecognized therapeutic avenue [102]. The 
cycles of nuclear import and export are governed by at 
least six types of protein–protein interactions, but only 
one enzymatic reaction occurs, namely the hydrolysis of 
GTP by RanGTPase. Our summarized Table 2 provides 
an overview of agents that are capable of interfering with 
nucleo-cytoplasmic trafficking and Figure 2 shows how 
the aberrant subcellular localization of proteins in cancer 
can be exploited by these agents as well as highlighting 
proteins/pathways yet to be specifically targetted.
Upstream manipulation of nucleo-cytoplasmic 
shuttling 
As the interaction of cargo proteins with transport 
receptors has been shown to be regulated by dynamic 
exposure to transport signals, the manipulation of the 
upstream regulatory processes has the potential to interfere 
with the location and function in a cargo-specific manner. 
Striking examples for upstream manipulation of nucleo-
cytoplasmic shuttling are compounds that interfere with 
the subcellular localization of FOXO transcription factors. 
Small molecules known to inhibit different elements 
of the PI3K/Akt signaling pathway such as broad and 
isoform-specific PI3K inhibitors, Akt inhibitors and 
PDK1 inhibitors decrease the activity of the downstream 
effector kinase Akt releasing FOXO proteins from their 
14-3-3 anchors [103-105]. In addition, Ca2+/Calmodulin 
inhibitors that descrease Akt phosphorylation also leads 
to the accumulation of FOXO reporter proteins in the 
nucleus of U2OS cells [106]. As FOXO proteins are 
inactivated in many human cancers through alterations in 
their subcellular localization the above mentioned agents 
hold promise to be effective anticancer drugs restoring 
the FOXO tumor suppressor functions. Interestingly, 
Trifluoperazine hydrochloride (TFP), an FDA-approved 
antipsychotic and antiemetic inhibits FOXO1 nuclear 
export (107) and restored sensitivity to AKT-driven 
erlotinib resistance in both cell culture and xenograft 
models of lung adenocarcinoma [108].
Additional examples of transcription factors 
whose subcellular localization can be influenced by 
small chemical compounds include the cancer-relevant 
proteins NFAT and NF-κB. The immunodepressive 
drugs cyclosporin A and FK506 inhibit the phosphatase 
activity of calcineurin and, in turn, the dephosphorylation-
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Figure 1: Potential therapeutic targets at different level of the nucleo-cytoplasmic transport process. Therapeutic agents 
such as small molecules or biologics targeting nucleo-cytoplasmic transport of oncoproteins or tumor suppressor proteins can interfere with 
upstream regulatory components (I), the interaction between cargo proteins and the transport receptors (II), the interaction between the 
transport receptors and the Ran regulators (III) and the NPC (IV). 
Figure 2:The subcellular distribution of oncogenes and tumor suppressors in normal cells and their redistribution 
following transformation. A schematic indicating the subcellular localization of key protein in normal (left hand side) and cancer cells 
(right hand side). Transport receptors (TR) are broadly indicated within normal cells however we highlight specific nuclear import/export 
proteins and indicate specific agents (numbered 1-26 and listed in Table 2) that can target the aberrant protein localization within a number 
of cancers. As can be seen in the figure, significant components of these aberrant pathways (particularly Ras, Rb and β-catenin subcellular 
localization) have yet to be targeted
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mediated unmasking of the NLS in the nuclear factor of 
activated T cells (NFAT) transcription factor, preventing 
its nuclear import. More specific inhibitors of NFAT–
calcineurin association (e.g. INCA) have been developed 
and were shown to inhibit nuclear NFAT localization 
[109]. Furthermore and consistent with its inhibitory effect 
on I-κBα phosphorylation and NF-κB activation BAY 
11-7082 has been identified as a specific inhibitor of the 
nuclear import of NF-κB [110].
Inhibition of nuclear transport by interfering with 
NPC
Although the nucleoporin/transport receptor 
interaction represents an obvious target to inhibit the 
nucleo-cytoplasmic transport, it has not been explored 
extensively [111;112]. A recent study identified a 
peptidomimetic inhibitor of the importin-α/β mediated 
import that mimics the FXFG structure and might 
block the binding of importin β to nucleoporins [113]. 
Table 2: Examples of agents capable of interfering with protein trafficking.
Number Agent Type of Regulation Primary  target Translocation effect Reference
1). Trifluoperazine hydrochloride upstream regulation Dopamine receptor Nuclear FOXO localization [107] 
2). W13 upstream regulation Ca2+/Calmodulin Nuclear FOXO3a localization [106] 
3). ETP-45648 upstream regulation PI3K Nuclear FOXO localization [125]
4). Vinblastine upstream regulation Tubulin Nuclear FOXO localization [106]
5).  Akt inhibitor X upstream regulation Akt Nuclear FOXO localization [154]
6).  INCAs upstream regulation Calcineurin Cytoplasmic NFAT [109] 
7). BAY 11-7082 upstream regulation  IκB kinase [IKK] Cytoplasmic NF-κB [110]
8). CHS828 upstream regulation  IKK Cytoplasmic NF-κB [155]
9). SMIP001/004 upstream regulation  unknown Nuclear p27KIP localization [59]
10). Resveratrol upstream regulation  Sirt1 Nuclear FoxO1 [156]
11). Elliticine upstream regulation  unknown Increased nuclear p53 localization [157]
12). WGA NPC GlcNAc Unspecific nuclear exclusion [114]
13). cSN50 peptide Transport Receptor/Cargo Importin-α Cytoplasmic NF-κB, NFAT, AP1, STAT1  [119]
14). bimax1/2 peptide Transport Receptor/Cargo importin-α Cytoplasmic  SV40, NP [120]
15). Leptomycin B Transport Receptor/Cargo CRM1 nuclear NES containing proteins [27]
16). Anguinomycins Transport Receptor/Cargo CRM1 nuclear NES containing proteins [126]
17).  Goniothalamin Transport Receptor/Cargo CRM1 nuclear NES containing proteins [158] 
18). Ratjadone Transport Receptor/Cargo CRM1 nuclear NES containing proteins [128]
19). Valtrate Transport Receptor/Cargo CRM1 nuclear NES containing proteins [130] 
20). Acetoxychavicol acetate Transport Receptor/Cargo CRM1 nuclear NES containing proteins [159] 
21). 15d-PGJ2 Transport Receptor/Cargo CRM1 nuclear NES containing proteins [160]
22). Peumusolide A unknown CRM1 Nuclear ERK [159] 
23). PKF050-638 Transport Receptor/Cargo CRM1 nuclear NES containing proteins [134] 
24). SINE Transport Receptor/Cargo CRM1 nuclear NES containing proteins [2]
25).  KOS-2464    Transport Receptor/Cargo CRM1 nuclear NES containing proteins [135]
26).  CBS9106 Transport Receptor/Cargo CRM1 nuclear NES containing proteins [136] 
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Monoclonal antibodies directed against nucleoporins 
have been used successfully in rat liver nuclear envelopes 
to prevent cargo association with the NPC and block the 
translocation of proteins [114]. Nuclear import can also 
be blocked by wheat germ agglutinin (WGA), but the 
mechanism underlying treatment with this agent is not 
fully understood [115]. 
Interference with the receptor/RanGTP 
interaction
The high nuclear concentration of RanGTP 
regulates the disassembly of the import complex and 
the formation of the export complex in the nucleus. 
Several recent studies report the identification of small 
molecule compounds capable of disrupting the binding 
of importin β to RanGTP. Affinity-based screening by 
confocal nanoscanning was used to identify several 
structurally related high affinity binders of importin β 
[116]. A pyrrole compound was shown to interfere with 
the interaction between importin β and RanGTP that 
blocked the nuclear import of GFP-NFAT in HeLa cells. 
This agent has been named Karyostatin 1A. Sonderholm 
et al. used FRET-based high throughput small molecule 
screen to investigate the protein-protein interaction 
between importin β and RanGTP. The authors reveal that 
importazole, a 2,4 diaminoquinazoline specifically blocked 
importin-β-mediated nuclear import both in Xenopus egg 
extracts and cultured cells without the disruption of either 
transportin-mediated nuclear import or CRM1-mediated 
nuclear export [117].
Competitive inhibition of cargo/receptor 
interaction
Competitive inhibition of the cargo protein and 
transport receptor represents an alternative approach to 
modulate the nucleo-cytoplasmic transport of proteins. 
Although the use of peptides carrying transport signals 
to displace the nuclear import or export of cargos from 
their transport receptors is an attractive therapeutic 
strategy, to date it has not yet been exploited in cancer 
therapy. Early work revealed that the cell-permeable 
peptide cSN50 carrying the NLS of the NF-kB inhibits 
not only the nuclear import of NF-kB, but also of other 
stress-responsive transcription factors including AP1, 
NFAT and STAT1 despite the presence of diverse NLS 
within these proteins [118;119]. Since these proteins have 
been reported to play important roles in several human 
malignancies this approach might prove to be an efficient 
anti-cancer therapeutic. Structure-based design has been 
used to generate the nuclear import inhibitor and M9M 
(which specifically interferes with Kapβ2) prevented 
the nuclear entry of cargo proteins containing a NLS 
with a R/H/Kx(2–5)PY motif. Conversely, Kosugi et 
al. employed an experimental strategy to obtain general 
inhibitors of the importin-α/β pathway based on the 
activity profiling of systematically mutated NLS peptide 
templates [10;120]. Using this method, the peptides 
bimax1 and bimax2 (which bind tightly to importin-α 
independently of importin-β) conferred resistance to cargo 
release activities in the nucleus. However, natural peptides 
are generally considered as poor drug candidates due to 
the ease that they are degraded by host cell enzymes, their 
low bioavailability, and their lack of specificity. 
Small molecule nuclear export inhibitors (NEIs)
Of all the potential targets regarding nuclear-
cytoplasmic transport, the export receptor CRM1 remains 
the best characterized therapeutic target. CRM1 is 
absolutely required for the nuclear export of many cancer 
related proteins such as p53, FOXO, Rb and Survivin. 
A major breakthrough regarding nuclear export 
inhibition resulted from the identification of CRM1 as the 
cellular target of the nuclear export inhibitor leptomycin 
B (LMB) [121]. A seminal study by Kudo et al. showed 
that LMB binds CRM1 at the conserved cysteine residue 
corresponding to position 528 of the human protein 
and 529 of the Schizosaccharomyces pombe protein 
[122]. Alkylation of this cysteine residue by LMB in the 
hydrophobic groove of CRM1 disrupts CRM1 binding to 
the leucine-rich NES of cargo proteins thereby preventing 
the formation of the CRM1-cargo-RanGTP export 
complex. Interestingly the Cys 528 residue is not essential 
for CRM1 function and mutant forms of CRM1 that carry 
a serine in this position can substitute for wildtype CRM1 
in mammalian cells [27]. However, a C258S substitution 
renders human cells completely resistant to LMB. LMB 
was the first specific inhibitor of nuclear export and is one 
of the striking examples of a small molecule compound 
capable of disrupting a protein-protein interaction, 
typically considered difficult to target. Unfortunately, 
when tested therapeutically LMB (elactocin) was found 
to exhibit severe dose-limiting toxicity as profound 
anorexia and malaise in a Phase I clinical trial [123]. 
Although, there are currently no inhibitors of the nuclear 
export in clinical trials, several different natural products 
as well as semi-synthetic and synthetic compounds have 
been identified and strategies are being developed to use 
them therapeutically. Several image-based high-content 
screening assays have been developed to assist the 
efficient identification of inhibitors of the nuclear export 
[124;125].
Natural compound NEIs
The LMB analogs Anguinomycins have been 
reported to be potent antitumor agents that are active in 
the picomolar range and display selective cytotoxicity 
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against transformed cells [126]. It is hypothesized that 
this selectivity is based on the interference with the pRb 
tumor suppressor. A truncated Anguinomycin analog 
was still capable of blocking nuclear export above 25nM 
[127] and based on this finding, Goniothalamin, a related 
natural compound was identified as a nuclear export 
inhibitor. The chemical structures of both compounds, 
the truncated Anguinomycin analog and Goniothalamin 
suggest that like LMB, they might irreversibly bind to 
Cys 528 of CRM1. Ratjadone, a compound structurally 
related to LMB, was obtained by Höfle et al. (1994) and 
shown to prevent nuclear export in an identical molecular 
mechanism to LMB [128]. Other natural compounds 
were identified including valtrate and acetoxychavicol 
acetate (ACA) isolated from Valeriana fauriei and Alpinia 
galangal, respectively as compounds that covalently bind 
to Cys 528 of CRM1 [129;130]. Although valtrate and 
ACA are being developed as anti-viral compounds, they 
might be also useful as anti-cancer agents. Interestingly 
the same group recently reported two natural products 
that retained their inhibitory activity when in the presence 
of a biotinylated probe derived from LMB suggesting an 
unknown NES non-antagonistic mode of action [131]. A 
very recent study demonstrates the power of phenotypic 
cellular high content analysis of natural extracts to identify 
specific inhibitors of the nuclear export [132]
Semi-synthetic and synthetic NEIs
PKF050-638 
Daelemans et al. identified the synthetic small 
molecule PKF050-638 with a molecular mass of 292.7 
kDa that reversibly disrupts CRM1-NES interaction in 
the micromolar range demonstrating strict structural 
requirements for its activity [133]. Structural studies on 
PKF050-638 revealed CRM1 inhibition and highlighted 
that the activity of these compounds was not solely 
correlated to the target cystine in CRM1, suggesting that 
more elements are involved [134].
Selective inhibitors of the nuclear export (SINE)
Based on various developed N-azolylacrylate 
analogs, the biopharmaceutical company Karyopharm 
Therapeutics developed orally active small molecule SINE 
compounds that irreversibly bound the Cys 528 residue 
within CRM1. These compounds are water soluble and 
have been shown to prevent the nuclear exit of HIV-Rev-
GFP, p53, FOXO and topoisomerase IIa [2]. SINEs were 
effective against various colorectal cancer cell lines and 
were well tolerated in these studies [2].
KOS-2464
A medicinal chemical approach conducted by Kosan 
Biosciences (Bristol-Myers Squibb) based on modifying 
LMB yielded several semi-synthetic LMB derivatives 
that maintain the high potency of LMB, but are up to 
16-fold less toxic than LMB in vivo [135]. The most 
potent derivative, KOS-2464 showed substantial efficacy 
in multiple mouse xenograft models and in contrast to 
cancer cells, KOS-2464 triggered cell cycle arrest, but 
not apoptosis in normal lung fibroblasts. Furthermore, the 
treatment of several p53 wild-type cell lines with KOS-
2464 led to an up regulation and nuclear localization of 
p53 [135]. These data suggest that toxicity associated 
with LMB is linked to “off target” effects and provide 
proof of concept that nuclear export can be inhibited with 
manageable toxicities in vivo.
Reversible nuclear export inhibitors
The high in-vivo toxicity of LMB might be due to its 
ability to covalently bind to Cys528 residue of CRM1 and 
irreversibly block the nuclear export of proteins. Therefore 
reversible nuclear export inhibitors hold significant 
promise to reduce toxic side effects and treat a range of 
cancers. Recently, scientists at the biopharmaceutical 
company CanBas have disclosed CBS9106, an orally-
active synthetic small molecule which reversibly prevents 
CRM1-mediated nuclear export and is currently being 
developed as an anti-cancer agent in preclinical trials 
[136] although the mechanism of its reversible binding 
remains to be elucidated [137]. In addition, CBS9106 
significantly reduces CRM1 protein levels without 
affecting CRM1 mRNA expression. This effect could 
be reversed by adding bortezomib or LMB suggesting 
that CBS9106-mediated CRM1 inhibition results in 
proteasome-dependent CRM1 degradation. CBS9106 
caused arrest of the cell cycle and induced apoptosis in 
a time- and dose-dependent manner for a broad spectrum 
of cancer cells while recovery was restored after removal 
of the drug. Oral administration of CBS9106 significantly 
suppressed tumor growth and prolongs survival in tumor 
bearing mice without a significant loss in body weight. 
A reduced level of CRM1 protein was also observed 
in tumor xenografts isolated from mice treated with 
CBS9106. Ongoing preclinical toxicology studies will 
determine whether this promising clinical candidate could 
be advanced to initial human clinical testing. Finally 
a recent patent application discloses a series of small 
molecule compounds as reversible inhibitors of the CRM1 
driven export of Hiv-Ref-GFP and Survivin-GFP for the 
treatment or prophylaxis of cancer or viral diseases (EP 2 
431 364 A1).
CONCLUSIONS
The therapeutic targetting of the nucleo-
cytoplasmic shuttling of macromolecules has emerged 
as a promising approach to treat human diseases. 
In particular, the subcellular localization of tumor 
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suppressors and oncogenic proteins is tightly regulated 
and essential for their function. Because the deregulation 
of intracellular protein transport is crucially involved in 
the pathophysiology of a broad range of human cancers, 
it offers novel molecular targets at many different 
levels to normalize or to interfere therapeutically with 
protein localization. The cargo proteins, the transport 
receptors, the Ran regulators and the NPC have been 
proposed as targets for therapeutic intervention, and in 
some cases agents have been developed to successfully 
influence subcellular protein distribution in disease 
states. The manipulation of the upstream regulatory 
processes has the potential to interfere with the location 
and function in a cargo-specific manner. Importantly, 
genetic or epigenetic alterations of upstream regulatory 
pathways known to drive tumorigenesis often lead to the 
aberrant localization of downstream effector proteins. 
As these cargo proteins retain a wild type phenotype 
their physiological homeostasis might be restored by 
relocalization. Pharmacological strategies to interfere 
with the general cellular nucleo-cytoplasmic transport 
machinery for anticancer therapy are limited as normal 
and cancer cells share similar core components of the 
export and import apparatus. However desired specificity 
could be achieved by several ways. Given the enormous 
complexity of the transport machinery and the number 
of involved proteins described in this review, a more 
comprehensive characterization of the nuclear import and 
export pathways for cancer-related proteins might reveal 
many specific therapeutic targets such as specific transport 
receptors or certain components of the NPC. At the 
moment, the only proteins of the transport apparatus being 
actively pursued as drug targets are CRM1 and importin-
α/ß, which are involved in the transport of many cellular 
proteins including tumor suppressor and oncogenic 
proteins. Several agents have been developed against 
these targets, some of them with promising therapeutic 
windows. In a personalized medicine context drugs with 
pleiotropic targets such as CRM1 or importin-α/ß might 
prove to be extremely effective and significantly improve 
patient prognosis. 
One of the major challenges of developing 
therapeutic agents to interfere with the nucleo-
cytoplasmic transport is the predominance of protein-
protein interactions over enzymatic reactions during the 
transport cycles. Targeting the flat and extended protein 
surfaces to disrupt protein-protein interactions using 
classical small molecule drug modalities has proven to 
be difficult. Conversely, Leptomycin B-like compounds 
and several recent studies indicate that protein–protein 
interfaces might be more tractable than has been thought 
[138]. Importantly, emerging technologies that are being 
used to bridge the pharmacologic gap between small 
molecules and protein therapeutics, including peptide 
stapling and fragment-based drug discovery hold promise 
to traverse the critical surface features of proteins [139]. In 
addition to the already available CRM1 and importin-α/ß 
inhibitors, agents that specifically interfere with alternative 
nuclear import and export pathways would be extremely 
useful as tool compounds for cell biology research have 
the potential to become therapeutic anti-cancer drugs at a 
time that they are vitally required [140].
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